{"nctId":"NCT03421379","briefTitle":"A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus","startDateStruct":{"date":"2018-02-21","type":"ACTUAL"},"conditions":["Diabetes Mellitus"],"count":75,"armGroups":[{"label":"Glucagon Nasal Powder","type":"EXPERIMENTAL","interventionNames":["Drug: Glucagon Nasal Powder"]},{"label":"Glucagon Hydrochloride Solution","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Glucagon Hydrochloride Solution"]}],"interventions":[{"name":"Glucagon Nasal Powder","otherNames":["LY900018"]},{"name":"Glucagon Hydrochloride Solution","otherNames":["GlucaGen®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants with Type 1 diabetes (T1D) or Type 2 diabetes (T2D)\n* Body mass Index (BMI) of 18.5 to 30.0 kilograms per meter squared (kg/m2) for T1D, or 18.5 to 35.0 kg/m2 for T2D\n* Hemoglobin A1c (HbA1c) ≤10%\n\nExclusion Criteria:\n\n* Have significant changes in insulin regimen and/ or unstable blood sugar control within the past 3 month\n* Have received a total daily dose of insulin \\>1.2 units per kilogram (U/kg)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia","description":"Percentage of participants who achieved treatment success during the controlled insulin-induced hypoglycemia in participants with type 1 diabetes mellitus (T1DM) and participants with type 2 diabetes mellitus (T2DM).Treatment success is defined as an increase in plasma glucose to greater than or equal to (≥) 70 milligrams per deciliter (mg/dL) or an increase of ≥20 mg/dL from plasma glucose nadir, without receiving additional actions to increase the plasma glucose concentration. Nadir is defined as the minimum plasma glucose concentration at the time of or within 10 minutes following glucagon administration.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM)","description":"PD assessment measured the change from Baseline in maximal blood glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride intramuscular (IM).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":"32"},{"groupId":"OG001","value":"119","spread":"33"}]}]}]},{"type":"SECONDARY","title":"PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM","description":"PD assessment measured the time to maximal concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":null},{"groupId":"OG001","value":"1.50","spread":null}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM","description":"PK assessment measured the change from baseline in the area under the concentration versus time curve from time zero to time t, where t is the last time point with a measurable concentration of Glucagon Nasal Powder and Glucagon Hydrochloride IM.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4830","spread":"89"},{"groupId":"OG001","value":"3240","spread":"32"}]}]}]},{"type":"SECONDARY","title":"PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM","description":"PK assessment measured the change from baseline in maximal concentration (Cmax) of glucagon nasal powder and glucagon hydrochloride IM.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9520","spread":"103"},{"groupId":"OG001","value":"3290","spread":"37"}]}]}]},{"type":"SECONDARY","title":"PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM","description":"PK assessment measured the change from baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":null},{"groupId":"OG001","value":"0.17","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":71},"commonTop":["Nausea","Vomiting","Rhinalgia","Blood pressure increased","Blood pressure decreased"]}}}